4.5 Review

Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies

期刊

EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 31, 期 3, 页码 235-247

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/13543784.2022.2040016

关键词

BRAF; KRAS-G12C; HER2; MSI; targeted therapy; liquid biopsy; colorectal cancer

向作者/读者索取更多资源

Molecular profiling has improved survival in metastatic colorectal cancer patients. Circulating tumor DNA has reshaped the prognosis of local CRC. Clinical guidelines recommend testing for multiple biomarkers to guide treatment.
Introduction Molecular profiling has led to significantly longer survival in metastatic colorectal cancer (CRC) patients. Clinical guidelines recommend testing for KRAS/NRAS, BRAF, and MSI status, and over the last few years, several promising new biomarkers have also been identified. Circulating tumor DNA has reshaped the prognosis of localized CRC. These genomic findings can guide treatment management to improve clinical outcomes. Areas covered Preclinical and clinical data over the last decade were reviewed for known and novel biomarkers with clinical implications in refractory and metastatic CRC. In the localized stage, all clinical trials involving new approaches such as liquid biopsy or neoadjuvant immunotherapy are also discussed. Molecular alterations and targeted agents are described, and data from completed and ongoing studies with targeted therapy and immunotherapies are presented. Expert opinion The implementation of liquid biopsies in the localized CRC setting has reshaped management of this disease. The expanded use of biomarkers to guide CRC patients' treatment has revealed a level of complexity arising from interactions between different biomarkers. Prevalence of most established targetable biomarkers is low; however, the number of identified biomarkers in CRC is increasing. Thus, metastatic CRC may ultimately be considered an umbrella diagnosis encompassing numerous rare disease subtypes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据